International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	OPTIMIZING THE SKIN BARRIER: A COMPREHENSIVE GUIDE TO SKINCARE IN ATOPIC DERMATITIS
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5904
RECEIVED	19 March 2026
ACCEPTED	27 June 2026
PUBLISHED	30 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

OPTIMIZING THE SKIN BARRIER: A COMPREHENSIVE GUIDE TO SKINCARE IN ATOPIC DERMATITIS

Julia Kret *(Corresponding Author, Email: juliakret99@gmail.com)*
Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
ORCID ID: 0009-0003-2780-8448

Zuzanna Rafałowska
University Clinical Hospital in Wrocław, Borowska 213, 50-556 Wrocław, Poland
ORCID ID: 0009-0003-6699-3121

Stanisław Rutz
Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
ORCID ID: 0009-0007-7918-9625

Anna Wojtala
Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
ORCID ID: 0009-0008-4082-0835

Aleksandra Wyrostkiewicz
Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
ORCID ID: 0009-0005-3679-7570

Jagoda Pałubska
SP ZOZ MSWIA w Kielcach im. św. Jana Pawła II, Kielce, Poland
ORCID ID: 0009-0000-3833-7977

Oliwer Muller
Szpital Kielecki św. Aleksandra sp. z o.o., Generała Tadeusza Kościuszki 25, 25-316 Kielce, Poland
ORCID ID: 0009-0005-6197-8461

Aleksander Sadkowski
Szpital Uniwersytecki nr 2 im. dr. Jana Biziela, ul. Ujejskiego 75, 85-168 Bydgoszcz, Poland
ORCID ID: 0009-0008-3300-2447

Paulina Bigda
Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
ORCID ID: 0009-0005-5022-6184

Jan Gdula
Szpital Specjalistyczny im. F. Ceynowy, ul. dr. A. Jagalskiego 10, 84-200 Wejherowo, Poland
ORCID ID: 0009-0007-9987-3758

Lilianna Zielińska
Plac Hirszfelda 12, 53-413 Wrocław, Poland
ORCID ID: 0009-0004-2471-841X

Michał Szpunar
Collegium Medicum w Bydgoszcz Uniwersytet Mikołaja Kopernika w Toruniu, Jagiellońska 15, 85-067 Bydgoszcz, Poland
ORCID ID: 0009-0000-5981-3696

Adrianna Zabiegałowska
Wojewódzki Szpital Zespolony im. Ludwika Rydygiera, ul. Św. Józefa 53-59, 87-100 Toruń, Poland
ORCID ID: 0009-0005-3048-0097

Magda Buśko
Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu, Jagiellońska 15, 85-067 Bydgoszcz, Poland
ORCID ID: 0009-0005-6451-8612

ABSTRACT

Introduction. Atopic Dermatitis (AD) is a complex, chronic, profoundly pruritic inflammatory dermatosis characterized by compromised epidermal barrier and relapsing-remitting course. While systemic therapies and targeted immunomodulators have revolutionized the management of moderate-to-severe disease presentations, the foundational pillar of AD management across all spectrums of severity remains the proactive restoration and maintenance of the stratum corneum. This comprehensive review summarizes clinical evidence regarding the pathophysiology of the atopic skin barrier, detailing the genetic implications of FLG loss-of-function mutations, the specific biochemical depletion of intercellular lipids (particularly ceramides), and the resultant microbiome dysbiosis driven by Staphylococcus aureus colonization.

Materials and Methods. A systematic, rigorous search of peer-reviewed literature was conducted to synthesize current, evidence-based practices regarding skin barrier optimization in Atopic Dermatitis. A comprehensive literature search was executed across major medical and scientific databases, primarily utilizing PubMed/MEDLINE, Google Scholar, the Cochrane Central Register of Controlled Trials and Embase. Data were extracted focusing on the biochemical properties of the skin barrier, the comparative efficacy of various emollient formulations, and the specific clinical outcomes related to proactive versus reactive treatment modalities. The extracted data were analyzed and structured to provide a cohesive guide that translates complex dermatological science into actionable clinical management strategies.

Results: The literature demonstrates that skin barrier dysfunction in Atopic Dermatitis is driven by FLG loss-of-function mutations, a distinct depletion of intercellular lipids (predominantly ceramides), and secondary Staphylococcus aureus microbiome dysbiosis. To counteract these defects, the evidence supports a foundational, multi-pronged barrier management approach. Successful strategies include evidence-based therapeutic bathing protocols, the precise application of targeted emollient classes, and the utilization of the "soak and smear" technique to lock in moisture. Furthermore, integrating these interventions with adjunctive pharmacotherapy, strict trigger avoidance, and comprehensive patient-centered education significantly enhances overall treatment efficacy and barrier integrity.

Conclusions: Proactive, continuous maintenance of the stratum corneum remains the indispensable foundation of AD management, regardless of disease severity. Rather than relying on reactive treatments for acute flare-ups, clinicians must shift toward a holistic paradigm of continuous barrier optimization. This proactive strategy is essential not only for managing structural and microbial skin defects but also for potentially arresting the atopic march and alleviating the profound psychosocial burden carried by AD patients.

KEYWORDS

Atopic Dermatitis, Emollients, Pruritus, Skincare, Atopy

CITATION

Julia Kret, Zuzanna Rafałowska, Stanisław Rutz, Anna Wojtala, Aleksandra Wyrostkiewicz, Jagoda Pałubska, Oliwer Muller, Aleksander Sadkowski, Paulina Bigda, Jan Gdula, Lilianna Zielińska, Michał Szpunar, Adrianna Zabiegałowska, Magda Buśko. (2026). Optimizing the Skin Barrier: A Comprehensive Guide to Skincare in Atopic Dermatitis. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5904

Introduction

Atopic Dermatitis (AD) is a complex, chronic, profoundly pruritic inflammatory dermatosis characterized by compromised epidermal barrier and relapsing-remitting course. While systemic therapies and targeted immunomodulators have revolutionized the management of moderate-to-severe disease presentations, the foundational pillar of AD management across all spectrums of severity remains the proactive restoration and maintenance of the stratum corneum. This comprehensive review summarizes clinical evidence regarding the pathophysiology of the atopic skin barrier, detailing the genetic implications of *FLG* loss-of-function mutations, the specific biochemical depletion of intercellular lipids (particularly ceramides), and the resultant microbiome dysbiosis driven by *Staphylococcus aureus* colonization.

Methodology

A comprehensive literature search was executed across major medical and scientific databases, including PubMed/MEDLINE, Google Scholar, the Cochrane Central Register of Controlled Trials, and Embase. The search strategy utilized targeted keywords and medical subject headings (MeSH) related to "Atopic Dermatitis," "skin barrier," "stratum corneum," "emollient formulations," and "proactive management." Data extraction was strictly focused on the biochemical and biophysical properties of the skin barrier, the comparative efficacy of various emollient classes, and specific clinical outcomes associated with treatment timing. Literature regarding core barrier tenets, such as evidence-based therapeutic bathing protocols and the strategic deployment of the "soak and smear" technique, was critically evaluated alongside data on adjunctive pharmacologic interventions, trigger avoidance strategies, and patient-centered education. The extracted qualitative and quantitative data were analyzed and structured to compare the clinical outcomes of a traditional, reactive "acute-flare" management paradigm against a proactive, continuous barrier maintenance strategy. The final synthesis prioritizes evidence that addresses both the structural integrity of the stratum corneum and the broader clinical goals of arresting the atopic march and alleviating the psychosocial burden of the disease.

Results

Definition and Epidemiology

AD is formally defined as a chronic, pruritic, inflammatory skin disease that typically follows a relapsing and remitting course (Frazier, 2020). It is frequently the initial step in the "atopic march" a well-documented progression of allergic diseases that begins with AD in infancy and often evolves into food allergies, allergic asthma, and allergic rhinitis later in life. (Dharmage et al., 2014). Globally, AD affects between 10% to 20% of children in developed countries, with the highest incidences observed in industrialized, urbanized environments (Langan et al., 2020). 90% of patients develop first symptoms in the first five years of life (Eichenfield et al., 2014). In infants, the condition typically manifests as erythematous papules and vesicles on the cheeks, scalp, and extensor surfaces of the limbs; however with time the distribution shifts toward the flexural folds (insides of the elbows and behind the knees) (Nutten, 2015). Contrary to older dogmas suggesting universal pediatric out-growth, contemporary longitudinal data indicate that up to 10% of adults worldwide suffer from persistent, recurrent, or adult-onset AD (Langan et al., 2020). Emerging data suggest a rapidly rising prevalence in developing nations and urbanizing centers, a phenomenon frequently attributed to the "hygiene hypothesis" (reduced early-life microbial exposure leading to Th2 immune skewing) alongside increased exposure to environmental pollutants and synthetic chemicals (Nutten, 2015).

The clinical impact of AD extends far beyond the cutaneous manifestations, profoundly affecting the quality of life (QoL) of both the patient and their caregivers. Pruritus is the hallmark symptom of AD and the primary driver of disease morbidity. The intense, often intractable itch leads to a compulsive "itch-scratch" cycle. Mechanical trauma from scratching physically excoriates the compromised stratum corneum, facilitating the ingress of aeroallergens, irritants, and microbial pathogens (Mack & Kim, 2018). This, in turn, stimulates a profound release of pro-inflammatory cytokines (such as IL-4, IL-13, and IL-31), which further amplifies the sensation of pruritus (Wollenberg et al., 2022). One of the most frequently mentioned by patients insidious consequence of AD is sleep disturbance. Up to 60% to 80% of children and adults experiencing an acute flare report significant sleep fragmentation due to nocturnal pruritus (Khosravi et al., 2024). Chronic sleep deprivation leads to neurocognitive deficits, behavioral disturbances in pediatric populations (often misdiagnosed as ADHD), and severe impairment in occupational productivity for adults (Zhang, 2025) Moreover, the visible, disfiguring nature of AD lesions, often localized to highly visible areas such as the face, neck, and hands, contributes to profound psychosocial distress. Adolescents and adults with moderate-to-

severe AD demonstrate significantly elevated rates of clinical anxiety, depression, social stigmatization, and suicidal ideation (Langan et al., 2020). It is important to note that the economic burden is also substantial, encompassing direct costs (physician visits, prescription medications, hospitalizations for secondary infections) and immense indirect costs (lost wages, reduced school attendance, and the extraordinary out-of-pocket "laundry and emollient burden" borne by families) (Thyssen et al., 2019).

The Barrier-First Approach

The pathophysiology of AD has long been debated through two distinct lenses: the "inside-out" hypothesis (primary immunological dysregulation driving secondary barrier damage) and the "outside-in" hypothesis (primary barrier defect facilitating secondary immunological sensitization) (Leung, 2000). Contemporary consensus acknowledges a synergistic overlap of both mechanisms. However, from a clinical management perspective, the foundation of treatment is unequivocally rooted in the "outside-in" approach. While topical immunomodulators (corticosteroids, calcineurin inhibitors) and advanced systemic therapies are essential for extinguishing acute, severe inflammatory flares (Sidbury et al., 2014), the foundational, indispensable treatment for all AD severities is proactive skin barrier restoration and maintenance. Without a physically intact, functional epidermal barrier, the skin remains highly permeable, and any immunological suppression achieved by pharmacotherapy will be transient, inevitably leading to relapse upon re-exposure to environmental triggers.

Pathophysiology of the Atopic Skin Barrier

To effectively optimize and repair the atopic skin barrier, clinicians must possess a deep understanding of its underlying biochemical and structural failures. The epidermal barrier, located in the uppermost layer of the skin (the stratum corneum), functions as a highly sophisticated, semi-permeable biosensor and physical shield. The architecture of the stratum corneum is classically described by the "bricks and mortar" model (Elias, 1983). The "bricks" are corneocytes—dead, flattened, highly keratinized cells. Filaggrin (filament-aggregating protein) is a critical structural protein synthesized in the stratum granulosum as a large precursor molecule, profilaggrin. As cells migrate upward to become corneocytes, profilaggrin is cleaved into filaggrin monomers, which bundle and compress keratin intermediate filaments. This bundling collapses the cell into a dense, flattened, structural "brick." Null mutations in the *FLG* gene are the single most significant known genetic risk factor for the development of AD. Approximately 30% to 50% of patients with moderate-to-severe AD harbor these mutations (Irvine et al., 2011). Consequently, their corneocytes are abnormally shaped, structurally weak, and poorly packed. Beyond its structural role, filaggrin degradation is vital for hydration. In the upper stratum corneum, filaggrin is broken down by specific proteases into amino acids and their derivatives, collectively known as Natural Moisturizing Factor (NMF) (Rawlings & Harding, 2004). NMF is highly hygroscopic (water-attracting). The profound lack of NMF in AD skin results in an inability to retain intracellular water, leading to a brittle, inflexible stratum corneum that is prone to micro-fissuring (Irvine et al., 2011). The "mortar" in the stratum corneum model consists of a highly organized extracellular lipid matrix composed primarily of three classes of lipids: ceramides (50%), cholesterol (25%), and free fatty acids (10-20%) (Elias, 2014). These lipids form dense, hydrophobic lamellar sheets that prevent water from escaping the body. In AD, there is not only a quantitative reduction in total epidermal lipids but a highly specific qualitative defect (Elias, 2014). AD skin exhibits a profound deficiency in specific long-chain ceramides, particularly Ceramide 1 (EOS) and Ceramide 3 (NP) (Janssens et al., 2012). Healthy skin relies on a precise 3:1:1 equimolar ratio of these lipids to maintain a highly organized, tightly packed orthorhombic crystalline structure. In AD skin, the altered lipid profile forces the matrix into a looser, more permeable hexagonal structure. (Man et al., 1993). This disorganized "mortar" cannot adequately seal the spaces between the corneocytes, leading to massive barrier dysfunction.

The structural and lipidic failures culminate in a measurable, dramatic increase in Transepidermal Water Loss (TEWL), the clinical gold standard for assessing barrier integrity (Alexander et al., 2018). The unabated evaporation of water leads to severe xerosis (dryness). Dry skin is less pliable; normal physical movement causes micro-tears in the stratum corneum, allowing allergens (e.g., house dust mites, pollens) and chemical irritants to penetrate deep into the viable epidermis, where they encounter Langerhans cells and trigger a systemic Th2 immune response. (Leung & Bieber, 2003).

Healthy human skin maintains a slightly acidic surface environment, known as the "acid mantle," with a pH ranging from 4.5 to 5.5. This acidity is crucial for the optimal function of lipid-processing enzymes and limits the growth of pathogenic bacteria (Schmid-Wendtner & Korting, 2006). In AD, the skin pH is

significantly elevated (more alkaline). This alkaline shift inhibits lipid synthesis and prematurely activates serine proteases (like KLK5 and KLK7), which inappropriately degrade the desmosomes holding skin cells together, causing premature, visible peeling and further damage. (Jang et al., 2016)

The healthy skin microbiome is a diverse ecosystem of commensal bacteria, fungi, and viruses that symbiotically protect against pathogens and modulate host immunity (Byrd et al., 2018). In AD, this microbial diversity collapses, leading to profound dysbiosis. Up to 90% of AD patients exhibit dense colonization of *Staphylococcus aureus* on both visibly lesional and non-lesional skin, compared to less than 5% in healthy individuals.*S. aureus* is not merely an opportunistic bystander; it actively drives the disease process. It secretes proteases that directly cleave epidermal structural proteins, exacerbating the barrier defect. More importantly, *S. aureus* releases exotoxins (such as staphylococcal enterotoxin B) that function as superantigens. These superantigens bypass normal antigen-presenting protocols, non-specifically activating massive numbers of T-cells and triggering a massive, uncontrolled release of pro-inflammatory cytokines, driving the acute eczema flare and creating an environment where the bacteria can thrive (Totté et al., 2016).

Therapeutic Bathing and Cleansing

Historically, clinical dogma frequently advised patients with AD to restrict bathing to once or twice a week to avoid "drying out" the skin. Contemporary, evidence-based dermatology has entirely reversed this stance. Regular, correctly executed bathing is an essential therapeutic intervention designed to hydrate the stratum corneum, mechanically remove environmental allergens and crusting, and reduce bacterial bioburden(Sidbury et al., 2014). However, the efficacy of bathing is entirely dependent on strict adherence to specific parameters. Bath water must be lukewarm, strictly maintained between 30°C and 34°C (86°F - 93°F). Exposure to hot water induces rapid peripheral vasodilation, which triggers the massive release of histamine from mast cells, instantly exacerbating intense pruritus. Bathing time should be strictly limited to 5 to 10 minutes (Pagliaro et al., 2024; Kim et al., 2015). While brief soaking hydrates the corneocytes, prolonged submersion physically macerates the skin and leaches out the water-soluble NMFs, paradoxically leaving the skin drier upon exiting the bath (Thomas, 2008). Vigorously rubbing the skin with a towel causes friction-induced micro-trauma and stimulates nerve endings, inducing itch (Sidbury et al., 2014). Patients must be instructed to gently "pat dry" the skin, intentionally leaving a slight film of moisture on the surface to prepare for emollient application. The choice of cleanser is critical; the wrong product can instantly strip the skin of its fragile lipid barrier. Traditional soaps, the alkaline true soaps (manufactured via the saponification of fats with an alkali like lye) typically have a pH of 9.0 to 10.0. They contain harsh anionic surfactants (like Sodium Lauryl Sulfate - SLS) that indiscriminately bind to and wash away both dirt and essential epidermal lipids (Mijaljica et al., 2022). Furthermore, they drastically raise the skin's pH, paralyzing lipid repair enzymes (Elias, 2014). Traditional alkaline soaps are strictly contraindicated in AD. Synthetic detergents (syndets) are the gold standard for atopic skin. They utilize highly specialized, mild surfactants (such as sodium cocoyl isethionate or various betaines) and are meticulously formulated to be pH-balanced (typically pH 5.0 to 6.0). They effectively emulsify dirt and external debris without extracting intercellular lipids or disrupting the acid mantle. (Mijaljica et al., 2022; Ananthapadmanabhan et al., 2004). Patients should be educated on the difference between "unscented" and "fragrance-free." "Unscented" products frequently contain masking chemicals (synthetic fragrances designed to neutralize the chemical odor of the product), which are notorious triggers for allergic contact dermatitis in the sensitized atopic patient (Panico et al., 2019). Only explicitly "fragrance-free" syndets should be utilized (Sidbury et al., 2014).

For patients suffering from frequent secondary bacterial infections, heavy crusting, or those demonstrating clinical signs of profound *S. aureus* colonization, the American Academy of Dermatology (AAD) provides a conditional recommendation for the use of dilute sodium hypochlorite (bleach) baths (Sidbury et al., 2014). When mixed with water, sodium hypochlorite forms hypochlorous acid, a potent broad-spectrum antimicrobial agent. Furthermore, research indicates that extremely dilute bleach concentrations exert intrinsic anti-inflammatory properties, effectively reducing the expression of inflammatory genes in the skin (Leung et al., 2013). The standard recommendation is 1/4 to 1/2 cup of regular strength, plain (no fragrance, no splashless formulations) 6% household bleach poured into a full, standard 40-gallon bathtub. The patient soaks for 10 minutes, focusing on affected areas while avoiding the face and eyes, followed by a thorough rinse with fresh, lukewarm water to remove residual chlorine, and immediate application of emollients. This is typically performed 2 to 3 times weekly (Sidbury et al., 2014).

Emollient Therapy & Barrier Repair

Emollients (moisturizers) are fundamental medical devices required for the lifelong management of AD. They serve as the artificial "mortar," providing a synthetic barrier while the skin attempts to heal its intrinsic defects. The consistent, liberal application of emollients has been universally proven to reduce disease severity, decrease the frequency of flares, and significantly exhibit a "steroid-sparing effect" reducing the total volume of topical corticosteroids required over a patient's lifetime (Barnes et al., 2013).

The efficacy of an emollient is heavily dictated by the timing of its application. The "Soak and Smear" and “3 minute rule” methodology are critical cornerstones of routine care. When a patient exits a bath, the corneocytes are temporarily engorged with water. However, due to the defective lipid barrier, this water will rapidly evaporate into the environment, if not immediately sealed. Emollients must be applied within 3 minutes of gently patting the skin dry, while it is still noticeably damp (Huang et al., 2009). This "smearing" creates an occlusive seal that traps the bathwater within the stratum corneum, resulting in profound, lasting hydration. Formulations generally contain a mixture of three primary functional classes. Humectants are highly hygroscopic molecules that attract and bind water. They draw moisture upward from the vascularized dermis into the avascular epidermis, and, in highly humid environments, can draw moisture from the ambient air (examples include: glycerin (glycerol), hyaluronic Acid, urea, propylene glycol, and alpha-hydroxy acids). High-concentration Urea (10% or higher) is particularly useful. In addition to being a humectant, it is a keratolytic, helping to dissolve the intracellular matrix in hyperkeratotic, heavily scaled, and thickened (lichenified) skin (Piquero-Casals et al., 2021). However, humectants applied alone in a dry climate can paradoxically pull water out of the skin and into the dry air; therefore, they must always be formulated with occlusives. Occlusives are dense, hydrophobic agents that form an impermeable, physical film over the surface of the stratum corneum, physically blocking the evaporation of water. Petrolatum (Petroleum Jelly) is the undisputed gold standard, capable of reducing the evaporation by up to 99%. Other examples include Mineral Oil, Lanolin (though lanolin allergy is a consideration in AD), Dimethicone (silicone), and Zinc Oxide (Sethi et al., 2016). While highly effective, heavy occlusives are often perceived by patients as cosmetically inelegant ("greasy" or "sticky"), leading to major adherence issues, particularly in adolescents (Sethi et al., 2016; Feldman et al., 2008). Lastly, the third group consists of emollients (the smoothers). True emollients are lipids and oils that do not necessarily form a thick barrier or attract water, but instead flow into the microscopic crevices and desquamating cracks between corneocytes. They lubricate the skin, dramatically improving texture, flexibility, and appearance (examples: Cetyl alcohol, Stearyl alcohol, Isopropyl myristate, Linoleic acid, and various natural botanical oils, for example sunflower seed oil) (Danby et al., 2013).

While standard over-the-counter moisturizers primarily mask the symptoms of dry skin by providing temporary occlusion, a newer class of Physiologic Lipid-Based Barrier Repair Devices attempts to directly repair the biochemical defect. The 3:1:1 Ratio: These advanced formulations are engineered to deliver a highly specific ratio of Ceramides, Cholesterol, and Free Fatty Acids (typically a 3:1:1 or 1:1:1 ratio). Because these ratios mimic the natural composition of healthy stratum corneum lipids, they are not merely sitting on the surface. They are actively taken up by the keratinocytes, transported into lamellar bodies, and secreted back into the extracellular space to genuinely rebuild the defective lipid lamellae. Clinical trials have demonstrated that ceramide-dominant formulations provide superior, long-lasting barrier restoration compared to standard petrolatum alone (Elias, 2018).

The latest evolution in non-prescription skincare is the "Emollient Plus", a moisturizer that incorporates active, non-pharmacologic ingredients designed to modulate the immune system or the microbiome. While traditional emollients focus strictly on passive physical repair creating an occlusive seal to trap water or pulling moisture into the skin, “Emollients "Plus" introduce non-pharmacological, biologically active molecules that actively manage the underlying biological triggers of skin irritation (Rachalewski et al., 2024). Non-viable bacterial components, such as *Vitreoscilla filiformis* lysate (grown in thermal spring water and commercially known as Aqua Posae Filiformis), which act as structural decoys (Prakoeswa et al., 2025). They stimulate the skin’s innate defenses and naturally suppress *S. aureus* colonization without acting like a harsh, broad-spectrum antibiotic (Prakoeswa et al., 2025). Specific oligofructans (like extracts from *Ophiopogon japonicus*) that selectively feed beneficial commensal bacteria, encouraging the microbiome to crowd out pathogens naturally (Rachalewski et al., 2024).

Moreover, extracts such as Licochalcone A (derived from the licorice root) provide targeted, steroid-free reduction of erythema (redness) by inhibiting cyclooxygenase and lipoxygenase inflammatory pathways (Kolbe et al., 2006).

Pharmacologic Interventions

Despite meticulous adherence to bathing and emollient protocols, the underlying immunological hyper-reactivity of AD means that breakthrough flares are inevitable for many patients. In these instances, skincare must be augmented with pharmacologic agents. The critical concept here is that pharmacotherapy and skincare are not mutually exclusive; they are synergistic. The traditional approach involved applying strong topical anti-inflammatory medications only when the skin exhibited visible erythema and intense pruritus, stopping the medication immediately upon clearance. (Wollenberg et al., 2020). This inevitably led to a continuous, frustrating cycle of recurrent flares and repetitive steroid use. Extensive clinical data now support proactive maintenance. Once an acute flare is cleared using intensive daily therapy, the patient transitions to applying a low-dose topical medication (like a low-potency steroid or a calcineurin inhibitor) strictly to the specific anatomical areas that frequently flare (e.g., the antecubital and popliteal fossae) twice weekly (e.g., weekends only), alongside daily whole-body emollient use (Thaci et al., 2008; Wollenberg et al., 2020). This suppresses sub-clinical, microscopic inflammation before it erupts into a full flare, dramatically increasing the time spent in remission and reducing the cumulative monthly steroid exposure (Al et al., 2026).

Topical corticosteroids have been the principal pharmacologic therapy for AD for over six decades. They work by binding to intracellular glucocorticoid receptors, translocating to the nucleus, and profoundly suppressing the transcription of multiple pro-inflammatory cytokines (Mehta et al., 2016). The vehicle (the base the steroid is mixed into) is almost as important as the active drug. Ointments (petrolatum-based) are overwhelmingly preferred in AD. They drive the steroid deeper into the skin due to their occlusive nature, they do not sting upon application to excoriated skin, and they contain very few potentially irritating preservatives. Creams and lotions contain high water content and thus require multiple preservatives and alcohols, which frequently cause burning and stinging on open eczematous lesions (Benson et al., 2019). Clinicians face massive hurdles regarding patient and parent fear of TCS side effects (specifically epidermal atrophy or "skin thinning"). Education is paramount. When utilized strictly according to modern guidelines: short, intensive bursts for acute flares followed by immediate tapering, and avoiding high-potency fluorinated steroids on delicate skin (face, neck, genitalia)—the safety profile of TCS is exceptionally high (Sidbury et al., 2023). To prevent under-treatment (which prolongs flares) and over-treatment (which risks side effects), patients must be taught the Fingertip unit method. One fingertip unit is the amount of ointment squeezed from a standard tube spanning from the tip of the adult index finger to the first crease. One FTU provides exactly enough medication to treat an area of skin equal to the size of two flat adult palms (Long & Finlay, 1991).

Topical Calcineurin Inhibitors (TCI), namely Tacrolimus ointment (0.03% and 0.1%) and Pimecrolimus cream (1%), represent a critical steroid-sparing alternative. They bind to the intracellular protein macrophilin-12, inhibiting the calcium-dependent phosphatase calcineurin. This halts the activation of the NFAT transcription factor, explicitly preventing T-cells from producing Th2 cytokines like IL-4 and IL-31. Because TCIs do not affect collagen synthesis, they do not cause skin atrophy, striae, or telangiectasia, regardless of the duration of use (Bieber, 2010). They are the absolute drug of choice for long-term control on highly sensitive, thin-skinned areas such as the eyelids, perioral region, neck, and intertriginous folds (Luger et al., 2021) The primary limiting factor is a localized sensation of severe burning or pruritus during the first 3 to 5 days of application. Patients must be heavily counseled to expect this and to push through the initial discomfort, as it reliably resolves as the inflammation subsides (Luger et al., 2021).

The armamentarium for AD has expanded significantly in recent years, targeting highly specific intracellular inflammatory pathways. Crisaborole 2% ointment is a non-steroidal molecule approved for mild-to-moderate AD. By inhibiting the PDE-4 enzyme, it prevents the degradation of cyclic adenosine monophosphate (cAMP) within immune cells. Elevated intracellular cAMP effectively dampens the release of a broad spectrum of inflammatory mediators. It is particularly useful for patients seeking entirely non-steroidal management regimens, though application site pain (stinging) remains a common side effect (Callender et al., 2019).

Ruxolitinib (janus kinase inhibitor) 1.5% cream represents a massive paradigm shift in topical therapy for localized, short-term management. The JAK/STAT pathway is the primary communication highway for key itch and inflammation cytokines (including IL-4, IL-13, and IL-31). By blocking this receptor, Ruxolitinib provides an astonishingly rapid reduction in intense pruritus, often extinguishing severe itch within 12 to 24 hours and promotes rapid clearance of localized, stubborn plaques (Simpson et al., 2024; Owji et al., 2022)

When a patient presents with a severe, recalcitrant, total-body flare that is unresponsive to standard topical application, Wet Wrap Therapy serves as an incredibly powerful, non-systemic "rescue" technique utilized to rapidly cool the skin and force the repair of the barrier. Following a lukewarm bath, the prescribed

topical medication (usually a mid-to-high potency TCS) is applied to the active inflammatory lesions. Secondly, thick layer of heavy emollient is applied to the rest of the body.

A layer of clean, damp (soaked in warm water and thoroughly wrung out) tubular cotton bandages, specialized eczema clothing, or even fitted cotton pajamas is applied closely over the skin. Next, a dry outer layer of clothing or dry bandages is placed over the wet layer to prevent evaporative cooling and chilling. The wraps are left in place for 2 to 6 hours, or ideally, overnight (Devillers et al., 2014). WWT works via multiple simultaneous mechanisms. The damp layer provides intense, sustained hydration to the parched stratum corneum. The dual layers provide massive occlusion, dramatically driving the penetration of the topical corticosteroid into the dermis. As the water slowly evaporates through the dry outer layer, it creates an evaporative cooling effect that physically constricts blood vessels, rapidly reducing severe erythema and halting the conduction of the itch sensation. Crucially, the physical barrier of the garments physically prevents the patient's fingernails from excoriating the skin, allowing the epidermis a critical window to heal without mechanical destruction (González-López et al., 2017).

Trigger Identification and Environmental Control

Optimal, diligent barrier care can be entirely undermined if the patient is continually subjected to external environmental insults that physically strip the barrier or biologically trigger the hyperactive Th2 immune system. Comprehensive management requires meticulous environmental control.

Common Irritants

Irritants are substances that physically or chemically damage the barrier, causing non-immunological inflammation.

Textile Engineering and Clothing: The physical structure of clothing fibers profoundly impacts AD. Wool fibers possess tiny, microscopic scales that physically catch and tear at the fragile corneocytes, inducing immediate severe mechanical pruritus. However some studies highlight that while traditional, coarse scaly wool triggers nociceptors and damages the epidermal barrier via friction, ultra-fine Merino wool (under 18 microns) actually benefits AD skin because the fibers are thin enough to bend rather than prick (Su et al., 2017). Fransen et al. conducted a massive retrospective study of nearly 10,000 dermatitis patients over 12 years. The authors found a significant association between atopic dermatitis and lanolin allergy, and stated that patch testing with lanolin (wool fat) is helpful in atopics with dermatitis and suspected cosmetic allergy. Rough synthetic fabrics like heavy polyester act similarly while simultaneously trapping heat and sweat. Patients must be directed to wear smooth, breathable fabrics: 100% long-staple cotton, high-quality bamboo, or specially engineered therapeutic silk (which is frequently coated with an antimicrobial finish and causes zero friction) (Murota et al. 2014).

Detergents and Solvents: Laundry detergents heavily laden with proteases, lipases, and synthetic fragrances easily remain bound to clothing fibers post-washing. Upon contact with atopic skin, these detergent residues (particularly protease enzymes) remaining on fabrics damage the stratum corneum, elevate skin pH, and trigger barrier breakdown in patients with AD. Furthermore, fabric softeners and dryer sheets, which coat clothing in heavily fragranced, cationic surfactants, must be strictly banned from the household (Christou et al., 2024).

Climate and Weather Extremes: AD is highly responsive to climatic shifts. In winter, the absolute humidity of the air plummets; central heating further dries the indoor air, essentially creating a vacuum that rapidly pulls water out of the skin (increasing TEWL). The use of high-capacity cool-mist humidifiers in the bedroom is essential. Conversely, in the summer heat, excessive diaphoresis (sweating) can trigger intense itch, as sweat contains trace amounts of urea and sodium that severely irritate micro-fissured skin (Bonamonte et al., 2019)

Allergen Considerations

Unlike irritants, allergens trigger a specific, IgE-mediated immune response.

Dust mites (*Dermatophagoides pteronyssinus*), pet dander, and seasonal pollen frequently exacerbate AD in genetically susceptible individuals. When the barrier is profoundly broken, these large protein molecules easily penetrate the dermis, encountering hyper-reactive immune cells. Environmental mitigation strategies, such as the use of high-quality HEPA air purifiers and impermeable dust-mite encasements for mattresses and pillows, provide a moderate reduction in flare frequency for sensitized individuals. (Nankervis et al., 2015)

There is a pervasive, almost universal misconception among parents that "something the child is eating" is the primary driver of their eczema. While it is true that up to 30% of children with moderate-to-severe AD have concomitant, true IgE-mediated food allergies (most commonly to cow's milk, eggs, peanuts, soy, and wheat), the food allergy is rarely the *cause* of the chronic skin condition (Fleischer et al., 2013). Routine, widespread, and unsupervised dietary elimination protocols based solely on the presence of AD are strongly discouraged by modern dermatological consensus. Unnecessary dietary restriction frequently leads to severe pediatric malnutrition, stunted growth, and profound psychosocial stress for the family (Sidbury, et al., 2014). Even more alarmingly, evidence from the LEAP (Learning Early About Peanut Allergy) study indicates that removing highly allergenic foods from the diet of an infant with a broken skin barrier can actually *cause* a life-threatening anaphylactic food allergy to develop later. Because the immune system is exposed to the food protein through the broken skin (which triggers an allergic Th2 response) without simultaneous exposure through the gut (which triggers a tolerogenic regulatory T-cell response), the body becomes highly sensitized (Du Toit et al., 2015). Food elimination should only ever be initiated if there is a clear, documented history of immediate clinical reaction (e.g., urticaria, lip swelling, anaphylaxis) within 2 hours of ingestion, confirmed by an allergist (Boyce et al., 2010).

Written Eczema Action Plans (WEAP)

To combat confusion, fear, and non-adherence, verbal instructions are wholly insufficient. Best practices dictate that every single patient must leave the clinic armed with a highly specific, easily understandable Written Eczema Action Plan (WEAP), conceptually modeled after asthma action plans. A standard WEAP utilizes a traffic-light system: The Green Zone (Everyday Maintenance): The skin looks and feels normal. The protocol dictates the specific daily bathing routine and the liberal, total-body application of emollients. Proactive maintenance therapy (e.g., applying a TCI to hot spots twice a week) is detailed here. The Yellow Zone (Mild to Moderate Flare): The skin is pink, slightly rough, and itching has commenced. The protocol details stepping up therapy to a mild topical steroid for a highly specific number of days, while continuing aggressive emollient use. The Red Zone (Severe Flare): The skin is intensely red, weeping, excoriated, and sleep is impossible. The protocol mandates the immediate initiation of high-potency rescue topical steroids, the commencement of Wet Wrap Therapy, instructions for utilizing bleach baths if infection is suspected, and clear contact parameters for emergency clinical evaluation (Powell et al., 2017)

Future Directions

As our comprehension of the atopic barrier deepens, the future of AD management lies in highly personalized, precision dermatological medicine. Future therapeutics may involve targeted microbiome transplantation (applying living, engineered commensal bacteria directly to the skin to permanently outcompete *S. aureus*) or genetically customized emollient profiles formulated based on a patient's specific *FLG* or *SPINK5* mutation phenotype (Hartmann et al., 2025). However, regardless of how advanced targeted biologics or gene therapies become, the fundamental laws of biophysics remain: the body must be protected from the environment. The diligent, proactive optimization of the stratum corneum will indefinitely remain the bedrock upon which all successful Atopic Dermatitis management is built.

Conclusions

The management of Atopic Dermatitis is an ultra-marathon, not a sprint. The foundational truth of this disease is that optimizing the skin barrier is a relentless, lifelong commitment. Clinical success is rarely, if ever, achieved through the prescription of a single "miracle cream." True, sustained clearance is achieved only through the disciplined, unyielding execution of a daily regimen of therapeutic cleansing and comprehensive moisturization. The most potent pharmaceutical agent ever engineered is entirely useless if it remains inside the tube. Treatment failure in AD is almost universally an issue of adherence, which frequently hovers below 40% in long-term studies (Sokolova & Feldman, 2015; Tan et al., 2026; Krejci-Manwaring et al., 2007). The exhaustive "soak and smear" routine, combined with the application of various topical medications to different body parts, is incredibly time-consuming and exhausting, leading to profound "treatment fatigue." A massive barrier to adherence is the "greasy" texture of the most effective occlusives. As mentioned earlier, many adolescents and adults flatly refuse to apply heavy petroleum ointments before school or work due to the feeling of stickiness and the staining of clothing (Patel & Feldman, 2021). In the context of shared decision-making, clinicians must pivot: if a patient refuses an optimal ointment but will consistently apply a sub-optimal cream or lotion, the cream becomes the more effective clinical choice simply because it will actually be utilized.

REFERENCES

1. Al, B., et al. (2025). Subclinical inflammation precedes atopic dermatitis relapses. *Journal of Allergy and Clinical Immunology, 155*(3), 033. https://doi.org/10.1016/j.jaci.2025.03.033
2. Ananthapadmanabhan, K. P., Moore, D. J., Subramanyan, K., Misra, M., & Meyer, F. (2004). Cleansing without compromise: The impact of cleansers on the skin barrier and the technology of mild cleansing. *Dermatologic Therapy, 17*(S1), 16–25. https://doi.org/10.1111/j.1396-0296.2004.04s1002.x
3. Barnes, T. M., & Greive, K. A. (2013). Use of bleach baths for the treatment of infected atopic eczema. *Australasian Journal of Dermatology, 54*(4), 251–258. https://doi.org/10.1111/ajd.12015
4. Bass, A., Anderson, K., & Feldman, S. (2015). Interventions to increase treatment adherence in pediatric atopic dermatitis: A systematic review. *Journal of Clinical Medicine, 4*(2), 231–242. https://doi.org/10.3390/jcm4020231
5. Benson, H. A. E., Grice, J. E., Mohammed, Y., Namjoshi, S., & Roberts, M. S. (2019). Topical and transdermal drug delivery: From simple potions to smart technologies. *Current Drug Delivery, 16*(5), 444–460. https://doi.org/10.2174/1567201816666190201143457
6. Boer, M., Duchnik, E., Maleszka, P., & Marchlewicz, M. (2018). Research techniques made simple: Transepidermal water loss measurement as a research tool. *Journal of Investigative Dermatology, 138*(11), 2295–2300.e1. https://doi.org/10.1016/j.jid.2018.09.001
7. Bonamonte, D., Filoni, A., Vestita, M., Romita, P., Foti, C., & Angelini, G. (2019). The role of the environmental risk factors in the pathogenesis and clinical outcome of atopic dermatitis. *BioMed Research International, 2019*, 2450605. https://doi.org/10.1155/2019/2450605
8. Boyce, J. A., Assa'ad, A., Burks, A. W., Jones, S. M., Sampson, H. A., Sicherer, S. H., Plaut, M., Tinkle, S. S., Byrd-Bredbenner, C., Fizer, E. S., Fineman, S. M., Furuta, G. T., Greenhawt, M. J., Li, J. T., Lemanske, R. F., Jr., Schneider, L. C., Smith, C., Staab, R., Teuber, S. S., & Schwaninger, J. M. (2010). Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-sponsored expert panel. *Journal of Allergy and Clinical Immunology, 126*(6 Suppl), S1–S58. https://doi.org/10.1016/j.jaci.2010.10.007
9. Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. *Nature Reviews Microbiology, 16*(3), 143–155. https://doi.org/10.1038/nrmicro.2017.157
10. Callender, V. D., Alexis, A. F., Stein Gold, L. F., Lebwohl, M. G., Paller, A. S., Desai, S. R., Tan, H., Ports, W. C., Zielinski, M. A., & Tallman, A. M. (2019). Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups. *American Journal of Clinical Dermatology, 20*(5), 711–723. https://doi.org/10.1007/s40257-019-00450-w
11. Carr, W. W. (2013). Topical calcineurin inhibitors for atopic dermatitis: Review and treatment recommendations. *Paediatric Drugs, 15*(4), 303–310. https://doi.org/10.1007/s40272-013-0013-9
12. Christou, D., Stevanovic, K., Evers, S., Weide, M., & Zuberbier, T. (2024). Evaluating the impact of laundry detergents on the skin microbiome of atopic dermatitis patients—A clinical study. *Health Science Reports, 7*(12), e70261. https://doi.org/10.1002/hsr2.70261
13. Danby, S. G., AlEnezi, T., Sultan, A., Lavender, T., Chittock, J., Brown, K., & Cork, M. J. (2013). Effect of olive and sunflower seed oil on the adult skin barrier: Implications for neonatal skin care. *Pediatric Dermatology, 30*(1), 42–50. https://doi.org/10.1111/j.1525-1470.2012.01865.x
14. Devillers, A. C. A., & Oranje, A. P. (2012). Wet-wrap treatment in children with atopic dermatitis: A practical guideline. *Pediatric Dermatology, 29*(1), 24–27. https://doi.org/10.1111/j.1525-1470.2011.01691.x
15. Dharmage, S. C., Lowe, A. J., Matheson, M. C., Burgess, J. A., Allen, K. J., & Abramson, M. J. (2013). Atopic dermatitis and the atopic march revisited. *Allergy, 69*(1), 17–27. https://doi.org/10.1111/all.12268
16. Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., Turcanu, V., Sever, M. L., Gomez Lorenzo, M., Plaut, M., & Lack, G. (2015). Randomized trial of peanut consumption in infants at risk for peanut allergy. *The New England Journal of Medicine, 372*(9), 803–813. https://doi.org/10.1056/NEJMoa1414850
17. Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., Cordoro, K. M., Davis, D. M., Krol, A., Margolis, D. J., Paller, A. S., Schwarzenberger, K., Silverman, R. A., Williams, H. C., Elmets, C. A., … Sidbury, R. (2014). Guidelines of care for the management of atopic dermatitis: Part 1: Diagnosis and assessment of atopic dermatitis. *Journal of the American Academy of Dermatology, 70*(2), 338–351. https://doi.org/10.1016/j.jaad.2013.10.010
18. Elias, P. M. (2014). Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1841*(3), 323–330. https://doi.org/10.1016/j.bbalip.2013.10.001
19. Fleischer, D. M., Spergel, J. M., Assa'ad, A. H., & Pongracic, J. A. (2013). Primary prevention of allergic disease through nutritional interventions. *The Journal of Allergy and Clinical Immunology: In Practice, 1*(1), 29–36. https://doi.org/10.1016/j.jaip.2012.09.003
20. Fransen, L., et al. (n.d.). Contact allergy to lanolin: Temporal changes in prevalence and association with atopic dermatitis. *Contact Dermatitis*. https://doi.org/10.1111/cod.12872

21. Fransen, M., Overgaard, L. E. K., Johansen, J. D., & Thyssen, J. P. (2017). Contact allergy to lanolin: Temporal changes in prevalence and association with atopic dermatitis. *Contact Dermatitis, 78*(1), 70–75. https://doi.org/10.1111/cod.12872
22. Frazier, W., & Bhardwaj, N. (2020). Atopic dermatitis: Diagnosis and treatment. *American Family Physician, 101*(10), 590–598.
23. González-López, G., Ceballos-Rodríguez, R. M., González-López, J. J., Feito Rodríguez, M., & Herranz-Pinto, P. (2017). Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: A systematic review and meta-analysis. *British Journal of Dermatology, 177*(3), 688–695. https://doi.org/10.1111/bjd.15165
24. Hartmann, D., Retamal, C., & Valenzuela, F. (2025). Precision medicine and treat-to-target approach in atopic dermatitis: Enhancing personalized care and outcomes. *Anais Brasileiros de Dermatologia*. Advance online publication. https://doi.org/10.1016/j.abd.2025.501135
25. Huang, J. T., Abrams, M., Tlougan, B., Rademaker, A., & Paller, A. S. (2009). Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics, 123*(5), e808–e814. https://doi.org/10.1542/peds.2008-2217
26. Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011). Filaggrin mutations associated with skin and allergic diseases. *New England Journal of Medicine, 365*(14), 1315–1327. https://doi.org/10.1056/NEJMra1011040
27. Jang, H., Matsuda, A., Jung, K., Karasawa, K., Matsuda, K., Oida, K., Ishizaka, S., Ahn, G., Amagai, Y., Moon, C., Kim, S.-H., Arkwright, P. D., Takamori, K., Matsuda, H., & Tanaka, A. (2016). Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model. *Journal of Investigative Dermatology, 136*(1), 127–135. https://doi.org/10.1038/JID.2015.363
28. Janssens, M., van Smeden, J., Gooris, G. S., Bras, W., Portale, G., Caspers, P. J., Vreeken, R. J., Hankemeier, T., Kezic, S., Wolterbeek, R., Lavrijsen, A. P., & Bouwstra, J. A. (2012). Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. *Journal of Lipid Research, 53*(12), 2755–2766. https://doi.org/10.1194/jlr.P030338
29. Khosravi, A., Glińska, J., & Barańska-Rybak, W. (2024). Sleep efficiency and neurocognitive decline in atopic dermatitis: A systematic review. *Acta Dermato-Venereologica, 104*. https://doi.org/10.2340/actadv.v104.40459
30. Kolbe, L., Immeyer, J., Batzer, J., Wensorra, U., Dieck, K. T., Mundt, C., Wolber, R., Stäb, F., Schönrock, U., Ceilley, R. I., & Wenck, H. (2006). Anti-inflammatory efficacy of Licochalcone A: Correlation of clinical potency and in vitro effects. *Archives of Dermatological Research, 298*(1), 23–30. https://doi.org/10.1007/s00403-006-0654-4
31. Koppelhus, U., Poulsen, J., Grunnet, N., Deleuran, M. S., & Obitz, E. (2014). Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: A randomized cross-over study comparing two efficient treatment modalities. *Frontiers in Medicine, 1*, Article 33. https://doi.org/10.3389/fmed.2014.00033
32. Kozłowska, K., & Mędraś, M. (2025). Genetic factors predisposing to atopic dermatitis: Selected genes related to the skin barrier and immune response. *Dermatology Review/Przegląd Dermatologiczny, 112*(1), 1–13. https://doi.org/10.5114/dr.2025.147775
33. Krejci-Manwaring, J., Tusa, M. G., Carroll, C., Camacho, F., Kaur, M., Carr, D., Fleischer, A. B., Jr., Balkrishnan, R., & Feldman, S. R. (2007). Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. *Journal of the American Academy of Dermatology, 56*(2), 211–216. https://doi.org/10.1016/j.jaad.2006.05.073
34. Langan, S. M., Irvine, A. D., & Weidinger, S. (2020). Atopic dermatitis. *The Lancet, 396*(10247), 345–360. https://doi.org/10.1016/S0140-6736(20)31286-1
35. Leung, D. Y. M. (2000). Atopic dermatitis: New insights and opportunities for therapeutic intervention. *Journal of Allergy and Clinical Immunology, 105*(5), 860–876. https://doi.org/10.1067/mai.2000.106484
36. Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. J., & Kim, S. K. (2013). Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice. *Journal of Clinical Investigation, 123*(12), 5361–5370. https://doi.org/10.1172/jci70895
37. Long, C. C., & Finlay, A. Y. (1991). The finger-tip unit—a new practical measure. *Clinical and Experimental Dermatology, 16*(6), 444–447. https://doi.org/10.1111/j.1365-2230.1991.tb01232.x
38. Mack, M. R., & Kim, B. S. (2018). The itch–scratch cycle: A neuroimmune perspective. *Trends in Immunology, 39*(12), 980–991. https://doi.org/10.1016/j.it.2018.10.001
39. Man, M. Q., Feingold, K. R., & Elias, P. M. (1993). Exogenous lipids influence permeability barrier recovery in acetone-treated murine skin. *Archives of Dermatology, 129*(6), 728–738. https://doi.org/10.1001/archderm.1993.01680270068010
40. Mehta, A. B., Nadkarni, N. J., Patil, S. P., Godse, K. V., Gautam, M., & Agarwal, S. (2016). Topical corticosteroids in dermatology. *Indian Journal of Dermatology, Venereology, and Leprology, 82*(4), 371–378. https://doi.org/10.4103/0378-6323.178903
41. Mijaljica, D., Spada, F., & Harrison, I. P. (2022). Skin cleansing without or with compromise: Soaps and syndets. *Molecules, 27*(6), 2010. https://doi.org/10.3390/molecules27062010

42. Murota, H., Yamaga, K., Ono, E., & Katayama, I. (2018). Sweat in the pathogenesis of atopic dermatitis. *Allergology International, 67*(4), 455–459. https://doi.org/10.1016/j.alit.2018.06.003
43. Nankervis, T. N., Baurecht, H., Montgomery, A. A., Thomas, K. S., Weidinger, S., & Apfelbacher, C. (2015). House dust mite reduction and avoidance measures for treating eczema. *Cochrane Database of Systematic Reviews, 2015*(1), CD008426. https://doi.org/10.1002/14651858.CD008426.pub2
44. Nutten, S. (2015). Atopic dermatitis: Global epidemiology and risk factors. *Annals of Nutrition & Metabolism, 66*(Suppl. 1), 8–16. https://doi.org/10.1159/000370220
45. Owji, S., Caldas, S. A., & Ungar, B. (2022). Management of atopic dermatitis: Clinical utility of ruxolitinib. *Journal of Asthma and Allergy, 15*, 1527–1537. https://doi.org/10.2147/JAA.S342051
46. Pagliaro, M., Pecoraro, L., Stefani, C., Pieropan, S., Piacentini, G., & Pietrobelli, A. (2024). Bathing in atopic dermatitis in pediatric age: Why, how and when. *Pediatric Reports, 16*(1), 57–68. https://doi.org/10.3390/pediatric16010006
47. Panico, A., Serio, F., Bagordo, F., Grassi, T., Idolo, A., De Giorgi, M., Guido, M., Congedo, M., & De Donno, A. (2019). Skin safety and health prevention: An overview of chemicals in cosmetic products. *Journal of Preventive Medicine and Hygiene, 60*(1), E50–E57. https://doi.org/10.15167/2421-4248/jpmh2019.60.1.1080
48. Patel, N., & Feldman, S. R. (2017). Adherence in atopic dermatitis. *Advances in Experimental Medicine and Biology*, 139–159. https://doi.org/10.1007/978-3-319-64804-0_12
49. Piquero-Casals, J., Morgado-Carrasco, D., Granger, C., Trullàs, C., Jesús-Silva, A., & Krutmann, J. (2021). Urea in dermatology: A review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties. *Dermatology and Therapy, 11*(6), 1905–1915. https://doi.org/10.1007/s13555-021-00611-y
50. Powell, K., Le Roux, E., Banks, J. P., & Ridd, M. J. (2018). Developing a written action plan for children with eczema: A qualitative study. *British Journal of General Practice, 68*(667), e81–e89. https://doi.org/10.3399/bjgp17X693617
51. Prakoeswa, C. R. S., Huda, B. K. N., Indrawati, D., Umborowati, M. A., Anggraeni, S., Damayanti, Murtiastutik, D., & Kerob, D. (2025). Effectiveness and tolerability of an emollient "plus" compared to urea 10% in patients with mild-to-moderate atopic dermatitis. *Journal of Cosmetic Dermatology, 24*(2), e70051. https://doi.org/10.1111/jocd.70051
52. Rachalewski, M., Pasikowska-Piwko, M., Dębowska, R., Marczak, I., Lendzion, K., Godziątkowski, H., Czarnomysy, R., Rogiewicz, K., & Eris, I. (2024). Biocompatibility and post-marketing surveillance study of emollient plus medical device cream containing oligofructans from *Ophiopogon japonicus* and acetyl heptapeptide-4 in atopic dermatitis skin care. *Cosmetics, 11*(4), 136. https://doi.org/10.3390/cosmetics11040136
53. Rawlings, A. V., & Harding, C. R. (2004). Moisturization and skin barrier function. *Dermatologic Therapy, 17*(Suppl. 1), 43–48. https://doi.org/10.1111/j.1396-0296.2004.04s1005.x
54. Rubin, C. B., & Brod, B. (2019). Natural does not mean safe—The dirt on clean beauty products. *JAMA Dermatology, 155*(12), 1344–1345. https://doi.org/10.1001/jamadermatol.2019.2724
55. Schmid-Wendtner, M. H., & Korting, H. C. (2006). The pH of the skin surface and its impact on the barrier function. *Skin Pharmacology and Physiology, 19*(6), 296–302. https://doi.org/10.1159/000094670
56. Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Blauvelt, A., Lebwohl, M. G., & American Academy of Dermatology. (2014). Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. *Journal of the American Academy of Dermatology, 71*(2), 332–349. https://doi.org/10.1016/j.jaad.2014.03.030
57. Sethi, A., Kaur, T., Malhotra, S. K., & Gambhir, M. L. (2016). Moisturizers: The slippery road. *Indian Journal of Dermatology, 61*(3), 279–287. https://doi.org/10.4103/0019-5154.182427
58. Simpson, E. L., Papp, K. A., Blauvelt, A., Chu, C. Y., Danby, S. G., Eichenfield, L. F., Hebert, A. A., Kuligowski, M. E., Venturanza, M. E., & Silverberg, J. I. (2024). Ruxolitinib cream monotherapy improved symptoms and quality of life in adults and adolescents with mild-to-moderate atopic dermatitis: Patient-reported outcomes from two phase III studies. *American Journal of Clinical Dermatology*. Advance online publication. https://doi.org/10.1007/s40257-024-00901-z
59. Sidbury, R., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Drucker, A. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., Silverberg, J. I., Singh, A. M., Wu, P. A., & Davis, D. M. R. (2023). Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies. *Journal of the American Academy of Dermatology, 89*(1), 128–129. https://doi.org/10.1016/j.jaad.2022.08.068
60. Su, J. C., Dailey, R., Zallmann, M., Leins, E., Taresch, L., Donath, S., Heah, S. S., & Lowe, A. J. (2017). Determining effects of superfine sheep wool in infantile eczema (DESSINE): A randomized paediatric crossover study. *British Journal of Dermatology, 177*(1), 125–133. https://doi.org/10.1111/bjd.15376
61. Tai, V. W. T., Oh, L. J. J., Yew, Y. W., & Li, B. K. (2026). Do medication beliefs influence adherence to topical therapies in patients with atopic dermatitis? *JEADV Clinical Practice, 2*(1), 1–13. https://doi.org/10.1002/jvc2.70295

62. Thaçi, D., Reitamo, S., Gonzalez Ensenat, M. A., Moss, C., Boccaletti, V., Cainelli, T., van der Valk, P., Buckova, H., Sebastian, M., Schuttelaar, M. L., & Ruzicka, T. (2008). Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: Results of a randomized, multicentre, comparative study. *British Journal of Dermatology, 159*(6), 1348–1356. https://doi.org/10.1111/j.1365-2133.2008.08813.x
63. Thomas, S. (2008). *The role of dressings in the treatment of moisture-related skin damage*. World Wide Wounds. http://www.worldwidewounds.com/2008/march/Thomas/Maceration-and-the-role-of-dressings.html
64. Totté, J. E., van der Feltz, W. T., Hennekam, M., van Belkum, A., van Zuuren, E. J., & Pasmans, S. G. (2016). Prevalence and odds of *Staphylococcus aureus* carriage in atopic dermatitis: A systematic review and meta-analysis. *British Journal of Dermatology, 175*(4), 687–695. https://doi.org/10.1111/bjd.14566
65. Wollenberg, A., Christen-Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin-Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., Kunz, B., Fölster-Holst, R., Trzeciak, M., Darsow, U., Szalai, Z., Deleuran, M., von Kobyletzki, L., Barbarot, S., Heratizadeh, A., … Ring, J. (2020). ETFAD/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *Journal of the European Academy of Dermatology and Venereology, 34*(12), 2717–2744. https://doi.org/10.1111/jdv.16892
66. Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen-Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink-Wagner, A. H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., … Flohr, C. (2022). European guideline (EuroGuiDerm) on atopic eczema – part II: Non-systemic treatments and treatment recommendations for special AE patient populations. *Journal of the European Academy of Dermatology and Venereology, 36*(11), 1904–1926. https://doi.org/10.1111/jdv.18429
67. Zhang, N., Chi, H., Jin, Q., Sun, M., Zhao, Y., & Song, P. (2025). Prevalence of sleep disorders in atopic dermatitis: A systematic review and meta-analysis. *Archives of Dermatological Research, 317*(1), 668. https://doi.org/10.1007/s00403-025-04176-0